Suchergebnisse - "Uchino, Junji"

PubPharm (9)

1

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients : The SPIRAL-0 Study

enthalten in: The oncologist | 2022

von Chihara, Y. | Takeda, T. | Goto, Y. | +20

ErratumIn: Oncologist. 2024 Mar 18;:. - PMID 38498842

2

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer : a prospective observational study

enthalten in: Translational lung cancer research | 2021

von Yoshimura, A. | Yamada, T. | Okuma, Y. | +21

3

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

enthalten in: Journal of clinical medicine | 2020

von Nakao, A. | Hiranuma, O. | Uchino, J. | +26

4

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Okura, N. | Nishioka, N. | Yamada, T. | +19

5

Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)

enthalten in: Clinical lung cancer | 2019

von Hiranuma, O. | Uchino, J. | Yamada, T. | +5

6

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment : A Phase II Trial

enthalten in: The oncologist | 2019

von Nakao, A. | Hiranuma, O. | Uchino, J. | +26

7

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

enthalten in: Cancers | 2019

von Yoshimura, A. | Yamada, T. | Okura, N. | +10

8

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

enthalten in: Nature communications | 2019

von Taniguchi, H. | Yamada, T. | Wang, R. | +21

9

Treatment rationale and design of the SPIRAL study : A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment

enthalten in: Medicine | 2018

von Uchino, J. | Nakao, A. | Tamiya, N. | +5

1
[1]